Verbascoside

Chemical Class	Phenylethanoid glycoside (caffeoyl-phenylethanoid ester)
Molecular Formula / CAS	C₂₉H₃₆O₁₅ · CAS 61276-17-3
Primary Botanical Source(s)	Olea europaea (olive leaf), Verbascum thapsus (mullein), Plantago lanceolata, Verbena officinalis
Plant Part	Leaf (olive, mullein, plantain, vervain)
Typical Content	A well-documented major phenolic constituent of olive leaf, alongside oleuropein and hydroxytyrosol
Solubility / Format	Water-soluble; well suited to aqueous and liquid extract formats
Sourcing Status	Product-live — genuine, documented constituent of olive leaf material
Buy from Herbuno	Olive Leaf Extract Powder · Olive Leaf Liquid Extract (Water Soluble)

Name origin: Verbascoside takes its name from Verbascum, the mullein genus in which it was first isolated and characterised in 1968; the compound is also widely known in the scientific literature under its alternate name, acteoside. Traditional use: Mullein leaf has a long folk-medicine history as a soothing preparation for sore throats, coughs and respiratory irritation across European herbal traditions, while olive leaf has separate but parallel traditional use across Mediterranean cultures for fever, wound care and general tonic purposes — uses that modern phytochemistry has since connected in part to shared phenolic constituents including verbascoside. Research trajectory: Verbascoside research began with basic isolation and structural work through the 1970s–90s, then expanded substantially from the 2000s onward into antioxidant, anti-inflammatory, antimicrobial and neuroprotective mechanistic studies as its wide distribution across unrelated medicinal plant families (Lamiales generally, plus olive) became apparent, with recent work increasingly focused on neurodegeneration and cerebrovascular models. Commercial source: Olive leaf is an established and well-documented dietary source of verbascoside, present alongside the better-known oleuropein and hydroxytyrosol as one of olive leaf’s core phenolic constituents.

---

Evidence for Verbascoside Applications

Verbascoside is a phenylethanoid glycoside formed from a caffeic acid unit esterified to a rhamnose-glucose disaccharide core bearing a hydroxytyrosol-derived phenylethyl group, and is widely distributed across the order Lamiales as well as in Olea europaea (family Oleaceae), one of the few documented exceptions to its otherwise Lamiales-concentrated distribution. A comprehensive pharmacological review credits it with antioxidant, anti-inflammatory, antineoplastic, wound-healing and neuroprotective activity across a substantial and still-growing research literature (Alipieva et al. 2014). Claim strength: Moderate.

In a rodent model of Alzheimer’s-relevant amyloid-beta toxicity, verbascoside treatment reduced endoplasmic-reticulum-stress markers and protected against amyloid-beta-induced cell damage in human glioma cells, with parallel benefit observed in APP/PS1 transgenic mice on learning and memory measures in the Morris water maze after six weeks of treatment (et al. 2020). This combines an in-vitro cell model with a genetic mouse model of amyloid pathology and has not been tested in human Alzheimer’s patients. Claim strength: Emerging.

Verbascoside has also shown protective effects in an experimental model of cerebral haemorrhage, where it suppressed TLR4-mediated acute inflammatory injury — a pathway implicated in the secondary tissue damage that follows intracerebral bleeding — building on earlier findings that verbascoside exerts neuroprotective effects in ischemic stroke models via a similar inflammatory-response target (Zhou et al. 2020). As with the Alzheimer’s research, this evidence is confined to animal injury models rather than human cerebrovascular patients. Claim strength: Emerging.

A separate line of research has examined verbascoside’s effect on platelet activity: a randomised clinical study reported that two weeks of oral administration of 100 mg verbascoside significantly reduced platelet aggregation in patients carrying cardiovascular risk factors, one of the relatively few verbascoside findings to come from a human clinical trial rather than a cell or animal model. This remains a single trial with a specific at-risk population and would need independent replication before broader cardiovascular claims could be supported. Claim strength: Moderate.

Verbascoside also carries documented antimicrobial activity, including synergistic effects when combined with conventional antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) in laboratory testing, alongside antioxidant, wound-healing and photoprotective activity that has drawn interest for topical dermo-cosmetic applications specifically. This body of evidence is predominantly in-vitro and topical-application focused rather than oral-supplementation focused. Claim strength: Moderate.

---

Dosage & Formulator Specification

No verbascoside-standardised extract exists in Herbuno’s current catalogue; the compound is sourced through general olive leaf extract material. The clinical trial demonstrating anti-platelet effects used an oral dose of 100 mg verbascoside daily for two weeks, but this represents a single trial in a specific population rather than an established dosing standard.

Analytical quantification of verbascoside is performed by HPLC with UV or diode-array detection, commonly used as a reference marker in olive-leaf and olive-byproduct phenolic profiling; formulators should request verbascoside-specific HPLC data rather than assuming a fixed ratio to the oleuropein or hydroxytyrosol content stated on a standardised-extract certificate of analysis.

Because verbascoside is water-soluble, aqueous and hydroalcoholic extraction methods are effective for its recovery, and Herbuno’s liquid extract format is well suited to formulations requiring a water-soluble phenolic profile. Formulators working in anhydrous or oil-phase systems should note that verbascoside will not partition into the lipid phase and should instead consider the powder format incorporated via an aqueous or hydrogel carrier.

Regulatory positioning follows established olive leaf food and botanical-ingredient precedent in most markets; olive leaf extract has a long history of dietary and topical use with no verbascoside-specific regulatory limit. Formulators making neuroprotective or platelet-related claims tied to verbascoside should note that the supporting clinical trial used an isolated 100 mg oral dose, which is a materially different exposure than typical olive-leaf-extract inclusion rates in a finished consumer formulation.

---

Frequently Asked Questions — Verbascoside

Related compounds: Oleuropein Aglycone, Hydroxytyrosol